China Recombinant Human Endostatin Market Share, Growth & Demand 2019-2023
Market Reports on China Provides the Trending Market Research Report on “China Recombinant Human Endostatin Market Report 2019-2023” under Life Sciences Category. The report offers a collection of superior market research, market analysis, competitive intelligence and Market reports. Recombinant Human Endostatin , an angiogenesis inhibitor, was developed by a Chinese enterprise in 1999 and approved by the China Food and Drug Administration (CFDA) in 2005 to be used in the combination chemotherapy for the recurrence and metastasis of NSCLC. Recombinant Human Endostatin acts on vascular endothelial cells to inhibit the movement of endothelial cells that form blood vessels and the formation of tumor angiogenesis and block the nutrition supply to tumor cells. In this way, it inhibits tumor proliferation or metastasis. Request a free sample copy of Recombinant Human Endostatin Market Report @ http://www.marketreportsonchina.com/marketreports/sample/reports/1745613 Description In 2...